Equipe Stéroïdes, Neuromodulateurs et Neuropathologies, EA-4438 Université de Strasbourg, Bâtiment 3 de la Faculté de Médecine, 11 rue Humann, 67 000 Strasbourg, France.
Pain. 2011 Jan;152(1):170-181. doi: 10.1016/j.pain.2010.10.015. Epub 2010 Nov 10.
Oxaliplatin (OXAL) is a platinum-based drug used for the treatment of colorectal, lung, breast and ovarian cancers. OXAL does not cause renal or hematologic toxicity. However, OXAL induces neuropathic pain which hampers the chemotherapy success. Attempts with neuroprotective agents including anticonvulsivants and antidepressants were made to prevent OXAL-induced painful neuropathy but the clinical data are controversial and the tested neuroprotectors are able to evoke themselves undesirable effects. Here, we demonstrated that the natural neurosteroid allopregnanolone (3α,5α-THP), known to be devoid of toxic side-effects in humans and experimental models, prevented and suppressed OXAL-induced painful neuropathic symptoms. Indeed, 3α,5α-THP repaired OXAL-evoked neurochemical and functional alterations in peripheral nerves and intra-epidermal nerve fibers (IENF). Behavioral analyses showed that prophylactic or corrective 3α,5α-THP treatment (4mg/kg/2days) respectively prevented or abolished OXAL-induced cold allodynia, mechanical allodynia and hyperalgesia by reversing to normal decreased thermal and mechanical pain thresholds of OXAL-treated rats. Electrophysiological investigations revealed that 3α,5α-THP restored control values of sciatic nerve conduction velocity and action potential peak amplitude drastically reduced by OXAL-treatment. Furthermore, immunohistochemistry and confocal microscopic quantifications demonstrated that 3α,5α-THP repaired OXAL-induced neurochemical/cellular alterations by restoring IENF control density and normal level of neurofilament 200kDa that was strongly repressed by OXAL in dorsal root ganglion neurons and sciatic nerve axons. OXAL showed no toxicity for the non-compact myelin protein 2',3'-cyclic-nucleotide-3'-phosphodiesterase whose expression level was similarly increased by 3α,5α-THP in controls and OXAL-treated rat nerves. Together, these results may be interesting for the development of natural or safe neurosteroid-based neuroprotective strategy against anticancer drug-evoked painful neuropathy.
奥沙利铂(OXAL)是一种用于治疗结直肠癌、肺癌、乳腺癌和卵巢癌的铂类药物。OXAL 不会引起肾毒性或血液毒性。然而,OXAL 会引起神经性疼痛,从而阻碍化疗的成功。人们尝试使用神经保护剂,包括抗惊厥药和抗抑郁药,来预防 OXAL 引起的痛性神经病,但临床数据存在争议,且测试的神经保护剂本身也会引起不良作用。在这里,我们证明了天然神经甾体孕烷醇酮(3α,5α-THP)可预防和抑制 OXAL 引起的痛性神经性症状,而众所周知,3α,5α-THP 在人类和实验模型中没有毒性副作用。事实上,3α,5α-THP 修复了 OXAL 引起的周围神经和表皮内神经纤维(IENF)的神经化学和功能改变。行为分析表明,预防性或矫正性 3α,5α-THP 治疗(4mg/kg/2 天)分别预防或消除了 OXAL 引起的冷感觉异常、机械性感觉异常和痛觉过敏,逆转了 OXAL 处理大鼠降低的热和机械痛觉阈值。电生理学研究表明,3α,5α-THP 恢复了坐骨神经传导速度和动作电位峰值幅度的对照值,而 OXAL 处理则大大降低了这些值。此外,免疫组织化学和共聚焦显微镜定量分析表明,3α,5α-THP 通过恢复 IENF 的对照密度和神经丝 200kDa 的正常水平来修复 OXAL 引起的神经化学/细胞改变,而神经丝 200kDa 在背根神经节神经元和坐骨神经轴突中被 OXAL 强烈抑制。OXAL 对非致密髓鞘蛋白 2',3'-环核苷酸-3'-磷酸二酯酶没有毒性,该蛋白的表达水平在对照组和 OXAL 处理的大鼠神经中也被 3α,5α-THP 同样增加。总之,这些结果可能对开发基于天然或安全神经甾体的神经保护策略以对抗抗癌药物引起的痛性神经病具有重要意义。